Prospective observational study on the efficacy and safety of EPA in advanced gastric cancer patients treated by S-1+CDDP as first line.
- Conditions
- gastric cancer
- Registration Number
- JPRN-UMIN000016226
- Lead Sponsor
- Kyushu medical center, medical oncology
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 30
Not provided
(1)Patients with active bleeding or beedingtendency (2)Patients who receive anticoagulant or antiplatelet drug (3)Patients without prior therapy with drugs or supplements contained icosapentaenoic acid (4)Patients with a history of allergy to icosapentaenoic acid (5)Patients scheduled for surgery (6)Patients scheduled for immune therapy (7)Patients with serious complication (8)Patients with immune-mediated illness (9)Patients with digestive symptom by ileus or gastrointestinal bleeding (10)Patients with symptomatic brain metastases or carcinomatous meningitis (11)Patients with massive pericardial effusion, pleural effusion or ascites *except for patients if effusions and ascites did not accumulate for more than two weeks after dranage therapy *include patients if pleurosclerosis was performed with anticancer drugs except OK-432 (12)Metachronous and synchronous double cancer (13)Bood tests positive for HBs antigen (14)Patients who receive continuous corticosteroid administration (15)Patients who receive drugs interact with S-1 or cisplatin (16)Uncontrolled psychiatry disease (17)Pregnant or lactating female and men who want to get partner pregnant (18)Judged inappropriate by the investigators
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method time to treatment failure(TTF) of a first-line chemotherapy
- Secondary Outcome Measures
Name Time Method rate of weight loss, alteration in nutritional status, alteration in Glasgow Prognostic score, QOL(Quality of life), adverse events, progression free survival, response rete, relative dose intense, translational research